The Retina Clinic London is now offering Direct Selective Laser Trabeculoplasty (DSLT) using the Alcon Voyager platform, one of the latest developments in glaucoma treatment technology.
This innovative laser treatment is designed to lower eye pressure in suitable patients without invasive surgery, and may reduce the need for long-term reliance on daily eye drops.
Unlike traditional laser procedures, the Alcon Voyager system delivers treatment without direct contact with the eye, helping to improve patient comfort while supporting highly precise treatment delivery.
Glaucoma is one of the leading causes of irreversible vision loss worldwide and is commonly linked to raised pressure inside the eye. Early detection and appropriate treatment are essential in helping to protect long-term vision.
The Alcon Voyager platform delivers laser treatment directly to the eye’s natural drainage system, known as the trabecular meshwork. Using automated treatment delivery and eye-tracking technology, the system applies 120 laser pulses through the limbus, the clear border area between the cornea and the white of the eye. This helps improve fluid drainage from the eye and reduce intraocular pressure in suitable patients.
Clinical evidence supports Voyager DSLT as an effective option for reducing eye pressure and medication burden. In the GLAUrious study, 62 percent of DSLT patients were medication-free at 12 months, while 81 percent were on the same or fewer glaucoma medications.
One of the major advantages of the procedure is the patient experience itself. The treatment is quick, comfortable and entirely non-contact. No contact lens is required during the procedure, and most patients report little or no discomfort.
The laser treatment itself takes only a few seconds per eye, and patients are typically able to return to normal activities shortly afterwards, subject to their consultant’s advice.
Professor Paulo-Eduardo Stanga, Founder and Chief Medical Officer at The Retina Clinic London, said:
“Direct SLT with the Alcon Voyager platform represents an important step forward in glaucoma care. The ability to deliver effective laser treatment without touching the eye improves both patient comfort and treatment precision. For many patients, this technology offers an opportunity to reduce their dependence on daily eye drops while helping to protect long-term vision.”
At The Retina Clinic London, DSLT is delivered within a consultant-led model of care, supported by advanced diagnostic imaging and specialist glaucoma expertise. Our glaucoma consultants work closely with the wider ophthalmic team to assess each patient carefully, determine whether DSLT is appropriate, and monitor treatment response over time.
This is particularly important because glaucoma care depends on precise diagnosis, careful pressure monitoring and a personalised long-term plan. For some patients, DSLT may help reduce the treatment burden of daily drops; for others, it may form part of a broader glaucoma management pathway.
The Retina Clinic London is currently the only private clinic in central London offering Direct Selective Laser Trabeculoplasty with the Alcon Voyager platform, giving patients access to one of the latest glaucoma laser technologies within a specialist, Harley Street Health District setting.
Aftercare is usually straightforward, and additional anti-inflammatory drops are not always required. A follow-up appointment is usually arranged around 10 to 12 weeks after treatment to assess the response and monitor eye pressure over time.
Patients interested in finding out whether Direct Selective Laser Trabeculoplasty with the Alcon Voyager platform may be suitable for them can contact The Retina Clinic London to arrange a consultation.
Call +44 (0)20 4548 5310 for further information.